Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026
Vast Therapeutics, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, today announced late-breaking Phase 1 data for its inhaled drug candidate ALX1, presented at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida.
Vast Therapeutics to Present Phase 1 Data on First-in-Class Nitric Oxide Therapy ALX1 at the American Thoracic Society 2026 International Conference
Vast Therapeutics, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, will present a late-breaking poster presentation demonstrating safety and pharmacokinetic data from the Phase 1 study of its inhaled drug candidate ALX1 at the American Thoracic Society (ATS) 2026 International Conference. ALX1 contains a first-in-class, small molecule nitric oxide prodrug designed to provide dual-action anti-inflammatory and anti-microbial activity without dose-associated toxicities. ATS 2026 will take place in Orlando, Florida from May 15-20.
